Qiagen : Q4 due today post Nasdaq closing - Expecting strong year-end finish, focus on 2022 guidance
>Strong finish to the year due to the pandemic - We forecast $ 559m in sales, an adj. EBIT of $ 195m (margin of 34.9%) and adj. EPS of $ 0.65 for Q4 2021, which is between 6% and 16% above the consensus (FactSet). We estimate in particular that the coronavirus pandemic has provided a boost for sales with coronavirus-related products again, an effect, we already observed in Q3. For Q4, we estimate sales with coronavirus-related products to have reached $ 170m vs $ 159m...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.